Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-378
Borofalan(10B)
Cat. No.
AKA-378
CAS No.
80994-59-8
MF
C9H12BNO4
MW
208.21
Borofalan can be used for Boron neutron capture research (BNCT). Borofalan can be used for the research of recurrent or locally advanced head and neck cancer.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Borofalan(10B)
Chemical name
10B-enriched L-4-BPA
CAS No.
80994-59-8
MF
C9H12BNO4
MW
208.21
Specifications
98%-102%
Description
Borofalan can be used for Boron neutron capture research (BNCT). Borofalan can be used for the research of recurrent or locally advanced head and neck cancer. Packing: 500g/bag，1kg/bag，5kg/bag Availability: In stock API Current Development Status: A3---Process Development / Scale-Up Reference: Aktin major API development processes: A1.Feasibility / Route Development A2.Laboratory Process Development A3.Process Development / Scale-Up A4.GMP Clinical Development A5.Commercial GMP Supply
Documents
-
Specification sheet
![]()
For Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS) etc., please enquiry by email: info@aktin.com
Storage and Shipping
Avoid light. Store in a sealed container.
References
[1].Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res. 1999;151(1):1-18.
[2].Barth RF, Soloway AH, Fairchild RG. Boron neutron capture therapy for cancer. Cancer Res. 1990;50(4):1061-1070.
[3].Barth RF, Vicente MG, Harling OK, et al. Current status of boron neutron capture therapy of cancer. Cancer Commun (Lond). 2018;38(1):35.
[4].Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (^10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 2021;155:182-187.
[5].Ishiwata K. 4-Borono-2-[18F]-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis. Ann Nucl Med. 2011;25(9):665-672.
Disclaimer
The information provided on generic APIs is for general reference and market assessment purposes only. Regulatory status, market availability, specifications, patents, and commercial terms may vary by country and change over time. Users should independently verify all information with the relevant regulatory authorities and qualified professionals before making any regulatory, manufacturing, investment, or commercial decisions. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-379
Bempedoic acid
CAS No.:738606-46-7
MF:C19H36O5
AKA-377
AkProva™ Metildigoxin
CAS No.:30685-43-9(acetone-free)
MF:C42H66O14.1/2C3H6O
AKA-376
AkProva™ beta-Acetyldigoxin
CAS No.:5355-48-6
MF:C43H66O15
AKA-375
Ak-NucleoVia™ Agrostemmoside E
CAS No.:2656438-29-6
MF:C84H128O45
AKA-374
Novobiocin sodium
CAS No.:1476-53-5
MF:C31H35N2NAO11
AKA-345
(-)Tetrahydropalmatine
CAS No.:483-14-7
MF:C21H25NO4
AKA-360
Travoprost
CAS No.:157283-68-6
MF:C26H35F3O6
AKA-359
Berberine sulfate
CAS No.:316-41-6
MF:C20H18NO4.1/2O4S
AKA-355
Topotecan hydrochloride
CAS No.:119413-54-6
MF:C23H24ClN3O5
AKA-354
Rimegepant Sulfate
CAS No.:1374024-48-2
MF:C56H64F4N12O13S
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
